Today: 7 February 2026
Subscribe
Browse Category

Mergers & Acquisitions News 19 December 2025 - 21 December 2025

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Warner Bros. Discovery (WBD) Stock Week Ahead: Netflix Deal vs. Paramount Tender Offer Keeps Shares in “Merger-Arbitrage Mode”

Dateline: December 21, 2025 (Week Ahead: Dec. 22–26, 2025) Warner Bros. Discovery, Inc. Series A stock (NASDAQ: WBD) heads into a holiday-shortened week with the kind of headline-driven volatility that rarely shows up in “normal” media earnings models. The reason is simple: WBD is now trading less like a traditional entertainment company and more like a live deal—anchored between two competing paths to a potential takeover. On Friday’s close, WBD finished around $27.77, putting it almost exactly on top of the $27.75 per-share headline value Netflix is pitching to WBD shareholders—while still leaving a meaningful gap to Paramount Skydance’s $30.00
21 December 2025
···
Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce (CRM) Stock Week Ahead: Qualified Acquisition, Agentforce Meets ChatGPT, and Analyst Price Targets to Watch (Dec. 22–26, 2025)

Salesforce, Inc. (NYSE: CRM) heads into the Christmas holiday week with a busy backdrop for investors: fresh product distribution news for its Agentforce platform, a newly announced acquisition aimed at “agentic” marketing, and a market calendar that’s likely to amplify day-to-day volatility simply because liquidity is thinner than usual. As of Sunday, December 21, 2025, the latest available trade data puts Salesforce stock around $259.91, following Friday’s (Dec. 19) close. StockAnalysis For the coming week, CRM stock is less about an earnings catalyst (Salesforce just reported) and more about how investors handicap AI monetization, M&A integration, and macro-driven risk appetite
21 December 2025
···
BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin (BMRN) Stock Jumps on $4.8 Billion Amicus Deal: Latest News, Forecasts and Analyst Outlook for Dec. 21, 2025

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is ending 2025 with a bang. Shares surged on Friday, December 19, closing at $61.15—up 17.71% on the day—after the company announced a $4.8 billion all-cash acquisition of rare-disease peer Amicus Therapeutics. Trading volume spiked to roughly 18.5 million shares, far above BioMarin’s recent daily activity, underscoring how dramatically the market repriced the story in a single session. Investing.com+2Reuters+2 As of Sunday, December 21, 2025, the weekend narrative around BioMarin stock is dominated by that deal—and what it signals: a sharper pivot toward durable rare-disease commercial franchises, an attempt to reduce dependence on BioMarin’s fast-growing
21 December 2025
···
Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

Amicus Therapeutics Stock (FOLD) News: BioMarin’s $14.50 Cash Buyout, Deal Timeline, and the Latest Forecasts (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (NASDAQ: FOLD) has effectively shifted from a “biotech story stock” to a deal-driven stock. The reason is simple and decisive: BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire Amicus in an all-cash transaction priced at $14.50 per share, putting a hard cap on the near-term upside—unless a competing bid emerges. SEC+1 With U.S. markets closed for the weekend, the most recent close available is $14.18 (Dec. 19, 2025)—a roughly 30% one-day jump that pushed shares close to the deal price and turned the remaining gap into a classic merger-arbitrage spread. StockAnalysis Below
21 December 2025
···
Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered around Dec. 19–21, 2025. From the White House’s sweeping “most-favored-nation” (MFN) push on U.S. drug prices to BioMarin’s largest-ever acquisition and fresh FDA approvals, the setup into year-end has become more headline-sensitive than the calendar would suggest. Here’s what investors and traders should be watching in pharma stocks in the week ahead. Christmas week trading: shorter sessions, fewer buyers, faster
21 December 2025
·········
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $4.8B Cash Buyout at $14.50 Resets the Outlook (Dec. 20, 2025)

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) has abruptly shifted from a “rare-disease growth story” to a merger-arbitrage stock after BioMarin Pharmaceutical announced a definitive, all-cash acquisition valued at roughly $4.8 billion. The headline number for shareholders: $14.50 per share in cash, a premium of about 33% to Amicus’ prior close. Reuters+2BioMarin Corporate+2 On December 19, FOLD shares surged and closed at $14.18, just below the cash consideration—leaving a small spread that now reflects time to close, regulatory clearance, and deal risk rather than day-to-day biotech sentiment. Finviz+1 Below is a comprehensive roundup of the latest news, forecasts,
20 December 2025
···
ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow (NOW) Stock News on Dec. 20, 2025: Armis Deal Rumors, 5-for-1 Split, Analyst Targets and the 2026 Outlook

ServiceNow, Inc. (NYSE: NOW) heads into the weekend with investors still digesting one of the most turbulent stretches the enterprise software leader has seen this year: a fresh stock split, a confirmed AI acquisition closing, and intense market debate over whether a rumored $7 billion cybersecurity deal would be a smart strategic leap—or an expensive distraction. As of Saturday, Dec. 20, 2025, U.S. markets are closed. The most recent session (Friday, Dec. 19) ended with ServiceNow shares at $155.31, up 1.26% on the day, with trading volume jumping to roughly 25.1 million shares—far above recent averages. StockAnalysis+1 That modest Friday
20 December 2025
···
Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

Tether-Linked Buyers Close $200 Million Peak Mining Deal as Rumble Pursues $767 Million Northern Data Takeover

December 20, 2025 — Newly surfaced U.S. regulatory filings are putting sharper names and structures behind a $200 million divestment at the center of Tether’s expanding push from crypto into AI infrastructure. Peak Mining—the bitcoin-mining business that German AI and data center operator Northern Data agreed to sell—has been acquired by three entities listed in filings as Highland Group Mining Inc., Appalachian Energy LLC, and 2750418 Alberta ULC, just as Tether-backed video platform Rumble presses ahead with an all-stock plan to acquire Northern Data. SEC+1 The convergence of deals matters because Northern Data is majority-owned by a Tether entity, and
20 December 2025
····
BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin (BMRN) Stock Surges on $4.8B Amicus Deal: Latest News, Analyst Forecasts, and What to Watch Next (Dec. 20, 2025)

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) ended Friday’s session sharply higher after announcing a blockbuster rare-disease acquisition that immediately reframed the company’s growth story. Shares closed at $61.15, up about 17.7% on the day, with trading volume far above typical levels—classic “big-news repricing” behavior. Yahoo Finance The catalyst: BioMarin’s agreement to buy Amicus Therapeutics (NASDAQ: FOLD) for $14.50 per share in cash, valuing the deal at approximately $4.8 billion. BioMarin says the acquisition adds two marketed, growing therapies—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease)—plus U.S. rights to DMX-200 (a Phase 3 kidney-disease asset), while also resolving a key piece
20 December 2025
··
Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

Amicus Therapeutics Stock (FOLD) Surges as BioMarin Agrees to Buy the Rare-Disease Biotech for $4.8 Billion

December 20, 2025 — Amicus Therapeutics, Inc. (NASDAQ: FOLD) is suddenly trading like a classic merger-arbitrage stock after BioMarin Pharmaceutical (NASDAQ: BMRN) agreed to acquire the company in an all-cash deal valued at roughly $4.8 billion. BioMarin’s offer of $14.50 per share sparked a sharp re-pricing of Amicus shares, which have been hovering just below the bid as investors weigh deal timing, closing risk, and what the buyout means for Amicus’ two commercial rare-disease franchises—Galafold (Fabry disease) and Pombiliti + Opfolda (Pompe disease). SEC+1 Below is a detailed breakdown of the latest news (as of 20.12.2025), plus the most relevant
20 December 2025
·····
DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

DJT Stock News Today: Trump Media & Technology Group Jumps on $6B TAE Fusion Merger—Price, Forecasts, and Key Risks (Dec. 20, 2025)

Dec. 20, 2025 — Trump Media & Technology Group Corp. (NASDAQ: DJT) is back in the spotlight after announcing a surprise all-stock merger with nuclear fusion company TAE Technologies—a deal the companies describe as valued at more than $6 billion and aimed at accelerating the buildout of a utility-scale fusion power plant. GlobeNewswire+1 The announcement sparked a sharp rally in DJT stock, which surged more than 40% on Dec. 18 and remained highly active as traders repositioned around what many see as a dramatic pivot: from a money-losing social media business to a long-dated, high-uncertainty bet on the future of
20 December 2025
··
Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media (DJT) Stock Jumps After $6 Billion Fusion Merger Plan: Latest News, Forecasts, and What Investors Are Watching (Dec. 20, 2025)

Trump Media & Technology Group Corp. (NASDAQ: DJT) is ending the week the way it often lives: loudly, unpredictably, and with traders glued to their screens. After announcing a surprise plan to merge with nuclear fusion developer TAE Technologies in a deal valued at more than $6 billion, DJT shares ripped higher on massive volume—turning a social-media stock into (at least on paper) a new way to bet on the race to power the AI era. GlobeNewswire+2StockAnalysis+2 As of the latest close Friday, Dec. 19, 2025, DJT finished at about $16.09, following a two-day surge that featured a roughly +42%
20 December 2025
···
Warner Bros. Discovery stock today: Netflix deal vs Paramount $30 bid, analyst forecasts, and what’s next — Dec. 20, 2025

Warner Bros. Discovery stock today: Netflix deal vs Paramount $30 bid, analyst forecasts, and what’s next — Dec. 20, 2025

Warner Bros. Discovery, Inc. stock has turned into a real-time market referendum on one question: which takeover path (if any) actually closes. As of the latest available quote, WBD shares were around $27.77, leaving the stock effectively pinned near Netflix’s agreed $27.75-per-share value while still sitting below Paramount Skydance’s $30 all-cash tender offer. That gap — roughly $2.23 per share, or about 8% upside to Paramount’s headline price — is the market’s way of pricing in deal friction: financing certainty, regulatory timing, and the messy mechanics of a split-up that has to happen before Netflix can consummate its purchase of
20 December 2025
····
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered around $14.18, after BioMarin Pharmaceutical announced a $14.50-per-share all-cash acquisition valuing Amicus at roughly $4.8 billion. Reuters+1 Because it’s a cash buyout, the story for Amicus stock is now less about “quarterly beats” and more about a single question: Will the deal close on time and on the stated terms? And that question—plus a few spicy subplots like patent litigation
20 December 2025
··
Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics (FOLD) Stock After Hours Dec. 19, 2025: BioMarin’s $14.50 Cash Buyout and What to Know Before the Next Market Open

Amicus Therapeutics, Inc. (NASDAQ: FOLD) ended Friday’s session (December 19, 2025) in a very different place than it started: the stock re-priced into “deal mode” after BioMarin Pharmaceutical (NASDAQ: BMRN) announced a definitive agreement to acquire Amicus in an all-cash transaction valued at roughly $4.8 billion. BioMarin Investors+2Reuters+2 With U.S. markets closed on the weekend, the “tomorrow open” investors are thinking about is really the next trading session on Monday, December 22, 2025—and the key question isn’t “growth vs. pipeline” anymore. It’s deal probability vs. deal timeline (and whether a rival bid emerges). SEC+1 What happened to Amicus Therapeutics stock
20 December 2025
SPX Technologies (SPXC) Stock News Today: Crawford United Deal, 2025 Guidance Raise, and Fresh Analyst Forecasts (Dec. 19, 2025)

SPX Technologies (SPXC) Stock News Today: Crawford United Deal, 2025 Guidance Raise, and Fresh Analyst Forecasts (Dec. 19, 2025)

SPX Technologies, Inc. (NYSE: SPXC) is having one of those “don’t confuse me with the S&P 500 index” days—because SPX is the index ticker many traders watch, while SPXC is the Charlotte-based engineered-products company riding powerful trends in HVAC and infrastructure equipment. On Friday, December 19, 2025, SPXC shares were volatile and finished lower on the day, even as the stock remains up sharply over the past year and analysts continue to debate how much upside is left after a big multi-year run. StockAnalysis+1 Below is a full, up-to-date breakdown of the latest SPX Technologies stock news, analyst price targets
19 December 2025
·
ABM Industries (ABM) Stock Slides After Earnings: Record 2025 Revenue, WGNSTAR Acquisition, Dividend Hike and 2026 Forecasts (Dec. 19, 2025)

ABM Industries (ABM) Stock Slides After Earnings: Record 2025 Revenue, WGNSTAR Acquisition, Dividend Hike and 2026 Forecasts (Dec. 19, 2025)

ABM Industries Incorporated (NYSE: ABM) is ending the week with investors debating a classic market paradox: record revenue and a bigger dividend on one side, and a sharp earnings miss plus fresh analyst caution on the other. On Friday, December 19, ABM shares traded around $41.78, down about 3.9% on the day, as the market continued to digest the company’s fiscal fourth-quarter report, its $275 million WGNSTAR acquisition agreement, and new Wall Street commentary. What happened to ABM stock this week? ABM’s volatility has been tied to a rapid sequence of headline catalysts: The initial reaction wasn’t uniformly negative. Reuters
19 December 2025
··
Caterpillar Stock (NYSE: CAT) Today: AI-Linked Rally Faces a Reality Check as Analysts Lift Targets and RPMGlobal Deal Advances

Caterpillar Stock (NYSE: CAT) Today: AI-Linked Rally Faces a Reality Check as Analysts Lift Targets and RPMGlobal Deal Advances

December 19, 2025 — Caterpillar, Inc. (NYSE: CAT) is ending the week in the spotlight after a sharp, multi-session pullback collided with fresh analyst target increases and a meaningful step forward in the company’s mining software expansion strategy. At last check on Friday, CAT traded around $576.56, up about 1.9% on the day after Thursday’s close, as broader U.S. equities climbed into year-end trading. Below is what’s driving Caterpillar stock on 19.12.2025, what Wall Street is forecasting for 2026, and what investors are watching next. Caterpillar stock’s volatile week: from record-high momentum to a five-day slide Caterpillar has been a
19 December 2025
···
ServiceNow (NOW) Stock Today: Post-Split Trading, Armis Deal Talk, Analyst Targets, and What Wall Street Is Watching on Dec. 19, 2025

ServiceNow (NOW) Stock Today: Post-Split Trading, Armis Deal Talk, Analyst Targets, and What Wall Street Is Watching on Dec. 19, 2025

ServiceNow, Inc. (NYSE: NOW) is back in the spotlight on December 19, 2025—this time for a mix of market mechanics and strategy that rarely collide so loudly in a single week: a fresh 5-for-1 stock split, unusually sharp volatility tied to blockbuster M&A rumors, and a renewed debate about how quickly enterprise software leaders can turn “agentic AI” into real, recurring dollars. As of the latest available quote on Dec. 19, ServiceNow shares were trading around $155, after opening near $154 and moving in a roughly $153–$157 intraday range. That price action comes as U.S. equities broadly climbed on Friday
19 December 2025
··
DJT Stock News Today: Trump Media Shares Jump Again on Dec. 19 as $6 Billion TAE Fusion Merger Sparks Fresh Volatility

DJT Stock News Today: Trump Media Shares Jump Again on Dec. 19 as $6 Billion TAE Fusion Merger Sparks Fresh Volatility

Dec. 19, 2025 — Trump Media & Technology Group Corp. (NASDAQ: DJT) is trading sharply higher again on Friday, extending a stunning two-day move after the Truth Social parent announced an all-stock merger with nuclear fusion company TAE Technologies—a pivot that has Wall Street, retail traders, and policy watchers parsing the fine print in real time. Reuters The rally comes with a familiar DJT signature: heavy volume, fast price swings, and a debate that’s less about near-term earnings and more about narrative—this time, the idea that fusion energy could become a critical power source for the AI boom. Barron’s+1 DJT
19 December 2025
··
1 2 3 4 5 6 … 20

Stock Market Today

Energy stocks set for a geopolitical week after Iran warning and oil rebound

Energy stocks set for a geopolitical week after Iran warning and oil rebound

7 February 2026
U.S. energy stocks rose Friday, with the S&P 500 energy sector up 1.88% and Exxon Mobil gaining 2.03%. Brent crude settled at $68.05 a barrel after Iran threatened U.S. bases if attacked. Saudi Aramco cut March Arab Light crude prices to a five-year low for Asia. Kazakhstan’s CPC Blend exports may drop 35% this month due to Tengiz oilfield disruptions.
Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

Financial services stocks rally as XLF jumps, Dow hits 50,000 — what to watch next week

7 February 2026
U.S. financial stocks rose Friday, with the XLF fund up 1.8% and the Dow closing above 50,000 for the first time, gaining 2.47%. Goldman Sachs jumped 4.3%, JPMorgan 3.9%, and Citigroup 6.0%. The Federal Reserve held rates steady, and San Francisco Fed President Mary Daly signaled possible cuts this year. Investors await January jobs and inflation data next week.
Go toTop